Pontus W. Lundberg

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Journal: British journal of haematology

Published: October 17, 2025

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Journal: Blood

Published: February 20, 2025

Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.

Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.

Journal: British journal of clinical pharmacology

Published: September 05, 2024

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.

Journal: American journal of hematology

Published: February 29, 2024

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.

Journal: HemaSphere

Published: February 18, 2024

Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.

Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.

Journal: American journal of hematology

Published: May 30, 2023

Genetic Factors in Familial Manifestation of Primary Mediastinal Large B-Cell Lymphoma over Two Generations.

Genetic Factors in Familial Manifestation of Primary Mediastinal Large B-Cell Lymphoma over Two Generations.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: April 26, 2023

Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.

Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.

Journal: European journal of haematology

Published: January 16, 2023

Case Report: Opposite Effects of BRAF Inhibition on Closely Related Clonal Myeloid Disorders.

Case Report: Opposite Effects of BRAF Inhibition on Closely Related Clonal Myeloid Disorders.

Journal: Frontiers in oncology

Published: September 19, 2021

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.

Journal: Annals of hematology

Published: October 13, 2020

Detection of the germline KIT S476I mutation in a kindred with familial mastocytosis associated with gastrointestinal stromal tumors.

Detection of the germline KIT S476I mutation in a kindred with familial mastocytosis associated with gastrointestinal stromal tumors.

Journal: The journal of allergy and clinical immunology. In practice

Published: July 22, 2020

MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages.

MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages.

Journal: Blood

Published: February 05, 2020

Showing 1-12 of 38

Last Updated: 09/26/2026